RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kiadis Pharma Stock

Kiadis Pharma Stocks 2024

Kiadis Pharma Stocks

36.62 M

Ticker

KDS.AS

ISIN

NL0011323407

WKN

A14VE3

In 2024, Kiadis Pharma had 36.62 M outstanding stocks, a 0% change from the 36.62 M stocks in the previous year.

The Kiadis Pharma Stocks history

YEARNUMBER OF STOCKS (undefined EUR)
2024e36.62
2023e36.62
2022e36.62
2021e36.62
202036.62
201927.39
201820.45
201714.95
201613.75
201510.69
201410.69
201310.69
201210.69

Kiadis Pharma shares outstanding

The number of shares was Kiadis Pharma in 2023 — This indicates how many shares 36.615 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kiadis Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kiadis Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kiadis Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kiadis Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kiadis Pharma Aktienanalyse

What does Kiadis Pharma do?

Kiadis Pharma NV was founded in 1997 in Amsterdam and is an innovative biotechnology company specializing in the development of cell therapies for the treatment of blood cancer diseases. The company is based in the Netherlands and is listed on the Euronext Amsterdam stock exchange. The business model of Kiadis is based on the development of therapies for patients with high medical needs, especially for individuals with severe blood cancer diseases for which there are no cure options. The company employs a proprietary platform technology that is based on the activation of T-cells for the therapy of cancer patients. Kiadis is currently developing various therapeutic approaches for the treatment of blood cancer diseases such as leukemia, lymphoma, and multiple myeloma. The company's main products are ATIR101 and ATIR201. ATIR101 is a cell therapy for patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) who require an allogeneic stem cell transplant. This therapy aims to reduce the risk of transplant rejection and graft-versus-host disease (GVHD), thereby increasing patients' chances of survival. ATIR201 is a therapy for the treatment of patients with multiple myeloma who require an allogeneic stem cell transplant. This therapy aims to reduce the risks of transplant rejection and GVHD, thereby increasing patients' chances of survival. Kiadis has also developed another platform technology called CytoSen, which is based on the activation of NK cells for the immunotherapy of cancer. The CytoSen technology aims to enhance the effectiveness of T-cell therapy by combining it with NK cells. Kiadis is continuously working to improve and expand its products and therapies. The company has a strong pipeline of product candidates at various stages of development targeting the treatment of leukemia, lymphoma, multiple myeloma, and other cancer diseases. The company has also entered into a partnership with Sanofi to accelerate the development of its therapies. Overall, Kiadis Pharma NV has an impressive history as an innovative company with a clear focus on the development of cell therapies for the treatment of blood cancer diseases. The company is dedicated to improving the lives of cancer patients and continuously works on the development of new therapies to improve the chances of survival and quality of life for cancer patients worldwide. Kiadis Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Kiadis Pharma's Shares Outstanding

Kiadis Pharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Kiadis Pharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Kiadis Pharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Kiadis Pharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Kiadis Pharma stock

How many stocks are there of Kiadis Pharma?

The current number of stocks of Kiadis Pharma is 36.62 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Kiadis Pharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Kiadis Pharma evolved in recent years?

The number of shares of Kiadis Pharma has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Kiadis Pharma as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Kiadis Pharma?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Kiadis Pharma pay?

Over the past 12 months, Kiadis Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kiadis Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Kiadis Pharma?

The current dividend yield of Kiadis Pharma is .

When does Kiadis Pharma pay dividends?

Kiadis Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kiadis Pharma?

Kiadis Pharma paid dividends every year for the past 0 years.

What is the dividend of Kiadis Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kiadis Pharma located?

Kiadis Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kiadis Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kiadis Pharma from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Kiadis Pharma pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Kiadis Pharma in the year 2023?

In the year 2023, Kiadis Pharma distributed 0 EUR as dividends.

In which currency does Kiadis Pharma pay out the dividend?

The dividends of Kiadis Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Kiadis Pharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Kiadis Pharma

Our stock analysis for Kiadis Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kiadis Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.